@book {7752,
	title = {Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: A retrospective analysis},
	series = {Open Access Journal of Urology},
	volume = {2},
	year = {2010},
	note = {Cited By :4Export Date: 21 February 2017},
	month = {2010},
	pages = {193 - 199},
	abstract = {Objective: Second-line treatment options in advanced urothelial cancer are limited. We investigated the efficacy of a methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) combination after failure of gemcitabine/platinum chemotherapy. Patients and methods: Twenty-five patients with advanced urothelial cancer, who received second-line MVAC after first-line gemcitabine/cisplatin (n = 9) or gemcitabine/carboplatin (n = 16), were included in this retrospective analysis. Results: Twenty-two patients (88\%) relapsed within 6 months after first-line treatment. Following MVAC, there were 5 (20\%) objective responses. Median follow-up was 20.2 months. Median progression-free survival (PFS) was 3.8 months (95\% CI: 2.3-5.2), and median overall survival (OS) was 9 months (95\% CI: 6.6-11.4). Eastern Cooperative Oncology Group performance status 0.1 versus 2 was associated with longer PFS (5 months versus 3.3 months, P = 0.049). Response or stabilization of disease during second-line chemotherapy predicted for a significantly longer PFS and OS (7.4 versus 3.5, P = 0.005; 15.5 versus 7, P = 0.046). Conclusions: Second-line MVAC chemotherapy may result in prolonged survival in some patients with refractory disease. Further research in this field is necessary. {\textcopyright} 2010 Karadimou et al, publisher and licensee Dove Medical Press Ltd.},
	keywords = {Bladder cancer, Mvac, Second line},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650729966\&doi=10.2147\%2fOAJU.S13122\&partnerID=40\&md5=67571d16d6ce29cf315295885e5c3cca},
	author = {Karadimou, A. and Lianos, E. and Pectasides, D. and Dimopoulos, M.A. and Bamias, A.}
}
